GSK plc (NYSE:GSK) Stock Holdings Raised by Sittner & Nelson LLC

Sittner & Nelson LLC raised its stake in GSK plc (NYSE:GSK) by 40.8% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 10,353 shares of the pharmaceutical company’s stock after purchasing an additional 3,000 shares during the period. Sittner & Nelson LLC’s holdings in GSK were worth $423,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of GSK. Primecap Management Co. CA increased its position in shares of GSK by 13.9% in the 2nd quarter. Primecap Management Co. CA now owns 14,511,390 shares of the pharmaceutical company’s stock worth $558,689,000 after purchasing an additional 1,773,020 shares during the last quarter. Mondrian Investment Partners LTD increased its position in shares of GSK by 37.8% in the 1st quarter. Mondrian Investment Partners LTD now owns 5,510,840 shares of the pharmaceutical company’s stock worth $236,250,000 after purchasing an additional 1,512,442 shares during the last quarter. Acadian Asset Management LLC increased its position in shares of GSK by 180.0% in the 1st quarter. Acadian Asset Management LLC now owns 2,219,798 shares of the pharmaceutical company’s stock worth $95,129,000 after purchasing an additional 1,426,935 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund bought a new stake in shares of GSK during the 2nd quarter valued at about $52,487,000. Finally, Kahn Brothers Group Inc. bought a new stake in shares of GSK during the 1st quarter valued at about $53,743,000. Institutional investors own 15.74% of the company’s stock.

Analysts Set New Price Targets

GSK has been the subject of a number of recent research reports. Argus raised shares of GSK to a “strong-buy” rating in a research report on Wednesday, August 7th. Barclays raised shares of GSK to a “hold” rating in a research report on Tuesday, August 27th. Finally, Guggenheim downgraded shares of GSK from a “buy” rating to a “neutral” rating in a research report on Thursday, October 31st. Five analysts have rated the stock with a hold rating, one has assigned a buy rating and three have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $50.00.

Insiders Place Their Bets

In other news, major shareholder Plc Gsk bought 2,791,930 shares of the firm’s stock in a transaction on Friday, September 27th. The stock was purchased at an average price of $8.00 per share, for a total transaction of $22,335,440.00. Following the transaction, the insider now owns 16,775,691 shares in the company, valued at approximately $134,205,528. This trade represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this link. 10.00% of the stock is owned by insiders.

GSK Price Performance

NYSE GSK opened at $36.66 on Friday. GSK plc has a 52 week low of $33.89 and a 52 week high of $45.92. The company has a current ratio of 0.81, a quick ratio of 0.53 and a debt-to-equity ratio of 0.98. The stock has a market cap of $75.98 billion, a price-to-earnings ratio of 23.81, a price-to-earnings-growth ratio of 1.42 and a beta of 0.66. The company has a 50-day moving average price of $40.25 and a two-hundred day moving average price of $40.97.

GSK Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, January 9th. Shareholders of record on Friday, November 15th will be given a $0.3928 dividend. This is a boost from GSK’s previous quarterly dividend of $0.38. The ex-dividend date of this dividend is Friday, November 15th. This represents a $1.57 annualized dividend and a yield of 4.29%. GSK’s dividend payout ratio is 100.00%.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.